Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.

Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors)

Liakos, Charalampos I., Papadopoulos, Dimitrios P., Sanidas, Elias A., Markou, Maria I., Hatziagelaki, Erifili E., Grassos, Charalampos A., Velliou, Maria L., Barbetseas, John D. · 2021 · American Journal of Cardiovascular Drugs

Abstract

The prevalence of arterial hypertension is high in patients with diabetes mellitus (DM). When DM and hypertension coexist, they constitute a dual cardiovascular threat and should be adequately controlled. Novel antihyperglycemic agents, including sodium-glucose co-transporter 2 (SGLT-2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and dipeptidyl peptidase-4 (DPP-4) inhibitors, have recently been used in the treatment of DM. Beyond their glucose-lowering effects, these drugs have shown beneficial pleiotropic cardiovascular effects, including lowering of arterial blood pressure (BP), as acknowledged in the 2019 European Society of Cardiology/European Association for the Study of Diabetes guidelines on diabetes, prediabetes, and cardiovascular diseases. The purpose of this review was to summarize the available information on the BP-reducing effects of these new glucose-lowering drug classes and provide a brief report on underlying pathophysiological mechanisms. We also compare the three drug classes (SGLT-2 inhibitors, GLP-1 RAs, and DPP-4 inhibitors) in terms of their BP-lowering effect and show that the greater BP reduction seems to be achieved with SGLT-2 inhibitors, whereas DPP-4 inhibitors have probably the mildest antihypertensive effect.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40256-020-00423-z

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 88 references

Cited by

See all 45

Metadata

Authors
Liakos, C. I., Papadopoulos, D. P., Sanidas, E. A., Markou, M. I., Hatziagelaki, E. E., Grassos, C. A., Velliou, M. L., & Barbetseas, J. D.
Affiliations
  • National and Kapodistrian University of Athens (GR)
  • Laiko General Hospital of Athens (GR)
  • NIMTS Hospital (GR)
  • University General Hospital Attikon (GR)
  • KAT General Hospital of Attica (GR)
Corresponding author
Liakos, Charalampos I.
Venue
American Journal of Cardiovascular Drugs
Published
2020-08-11
Volume
21
Issue
2
Pages
123-137
ISSN
  • 1175-3277 (ISSN-L)
  • 1179-187X
OpenAlex
W3048796875
Cited by
43
References
88
Citations by year
2026: 3 · 2025: 5 · 2024: 15 · 2023: 15 · 2022: 2 · 2021: 3
FWCI
0.77
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • American Journal of Cardiovascular Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
blood pressure reduction, SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, antihypertensive effect, diabetes mellitus, hypertension, cardiovascular risk, antidiabetic drugs, pathophysiological mechanisms
MeSH terms
Glucagon-Like Peptide-1 Receptor, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Blood Pressure, Diabetes Mellitus, Type 2, Humans, Hypertension, Hypoglycemic Agents, Meta-Analysis as Topic, Randomized Controlled Trials as Topic, Dipeptidyl-Peptidase IV Inhibitors, Arterial Pressure

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors). https://app.cochat.ai/papers/10.1007/s40256-020-00423-z
The paper
Liakos, C. I., Papadopoulos, D. P., Sanidas, E. A., Markou, M. I., Hatziagelaki, E. E., Grassos, C. A., Velliou, M. L., & Barbetseas, J. D. (2021). Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors). American Journal of Cardiovascular Drugs. https://doi.org/10.1007/s40256-020-00423-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.